ENDPOINTS

Cassava ends work on Alzheimer's drug; Alumis gets $40M upfront from Kaken

2 months ago

News Briefing

Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund

2 months ago

News Briefing

Genfit's up to €185M royalty deal; J&J’s Tremfya gets a Crohn's approval

2 months ago

News Briefing

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion's board

2 months ago

Peer Review

Elevation Oncology stops work on ADC, lays off workers; AstraZeneca’s CEPI funding

2 months ago

News Briefing

Empress Therapeutics confirms layoffs; Nanobiotix amends J&J deal terms

2 months ago

News Briefing

Vertanical’s Phase 3 win for non-opioid painkiller; Apriori lays off 40% of staff

2 months ago

News Briefing

Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M

2 months ago

News Briefing

Ascletis’ not-so-great weight loss data; Vivace’s $35M Series D

3 months ago

News Briefing

Corrected: Mineralys aims to raise $250M; Coherus' staffing changes

3 months ago

News Briefing

CytomX, Amgen pass on T cell engager; Molecular Partners ends work with Novartis

3 months ago

News Briefing

Corrected: Merck KGaA’s mixed Phase 2 lupus results; Zymeworks pauses work on ADC

3 months ago

News Briefing

Live updates: Makary likely a lock for next FDA chief after breezy Senate hearing

3 months ago

People

Pharma

Bristol Myers' MyoKardia unit ends work with Fulcrum; ALX discloses layoffs

3 months ago

News Briefing

Live updates: Trump NIH pick Bhattacharya sails through Senate hearing, sidestepping controversy

3 months ago

People

Pharma

Tenaya raises about $53M; BeiGene’s PD-1 gets a first-line approval

3 months ago

News Briefing

Genentech's TNKase gets new approval; Sanofi gives up rights to oncology candidate

3 months ago

News Briefing

Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeutics

3 months ago

News Briefing

Hansoh ends collaboration with Silence; Vir hunts for HBV drug partner

3 months ago

News Briefing

Harbour BioMed inks deal up to $395M; ORIC refines plans for two drugs

3 months ago

News Briefing

Repare to lay off 75% of staff; Castle Creek inks $75M royalty deal

3 months ago

News Briefing

FDA won’t allow Invivyd’s Pemgarda to treat Covid; Antibiotic biotech launches

3 months ago

News Briefing

More biotechs announce share buybacks; Cosette to buy Mayne Pharma

3 months ago

News Briefing

Illumina to lay off about 100 people; Incyte’s new AI partnership

3 months ago

News Briefing

about the author

author articles

Cassava ends work on Alzheimer's drug; Alumis gets $40M upfront from Kaken

Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund

Genfit's up to €185M royalty deal; J&J’s Tremfya gets a Crohn's approval

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion's board

Elevation Oncology stops work on ADC, lays off workers; AstraZeneca’s CEPI funding

Empress Therapeutics confirms layoffs; Nanobiotix amends J&J deal terms

Vertanical’s Phase 3 win for non-opioid painkiller; Apriori lays off 40% of staff

Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M

Ascletis’ not-so-great weight loss data; Vivace’s $35M Series D

Corrected: Mineralys aims to raise $250M; Coherus' staffing changes

CytomX, Amgen pass on T cell engager; Molecular Partners ends work with Novartis

Corrected: Merck KGaA’s mixed Phase 2 lupus results; Zymeworks pauses work on ADC

Live updates: Makary likely a lock for next FDA chief after breezy Senate hearing

Bristol Myers' MyoKardia unit ends work with Fulcrum; ALX discloses layoffs

Live updates: Trump NIH pick Bhattacharya sails through Senate hearing, sidestepping controversy

Tenaya raises about $53M; BeiGene’s PD-1 gets a first-line approval

Genentech's TNKase gets new approval; Sanofi gives up rights to oncology candidate

Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeutics

Hansoh ends collaboration with Silence; Vir hunts for HBV drug partner

Harbour BioMed inks deal up to $395M; ORIC refines plans for two drugs

Repare to lay off 75% of staff; Castle Creek inks $75M royalty deal

FDA won’t allow Invivyd’s Pemgarda to treat Covid; Antibiotic biotech launches

More biotechs announce share buybacks; Cosette to buy Mayne Pharma

Illumina to lay off about 100 people; Incyte’s new AI partnership